Levalbuterol — Membership Pricing
Levalbuterol is not confirmed for no-additional-cost pricing. Membership pricing may be available; confirm the price with the dispensing pharmacy.
Levalbuterol Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Membership pricing may be available |
| Typical Retail | $170.00 |
Membership pricing may be available; confirm the price with the dispensing pharmacy.
About Levalbuterol
Levalbuterol is a prescription medication. Ask your doctor if Levalbuterol is right for you.
Other strengths and forms of Levalbuterol
How to Check Levalbuterol Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Levalbuterol at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Respiratory & Allergies
What Levalbuterol is approved for (FDA label)
Levalbuterol inhalation solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol inhalation solution is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. (1)
Source: Read the full FDA label on DailyMed. Label effective date: December 24, 2024.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Boxed warning for Levalbuterol (FDA label)
For Oral Inhalation Only Levalbuterol Inhalation Solution is only for use with a nebulizer. Instructions for Using Levalbuterol Inhalation Solution
Source: FDA prescribing information (DailyMed). Set ID: 29eae75d-93da-7a5a-e063-6394a90ac0c0. SPL document ID: 29ead193-b33d-7f78-e063-6294a90a7ef4. Label effective date: December 24, 2024. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Levalbuterol (FDA label)
Inhalation Solution 3 mL unit-dose, vials in three dosage strengths of levalbuterol; 0.31 mg, 0.63 mg, 1.25 mg. Each strength of levalbuterol inhalation solution, USP is available in a shelf carton containing one or more foil pouches, each containing 12 unit-dose vials. Inhalation Solution (unit-dose vial for nebulization): 0.31 mg/3 mL, 0.63 mg/3 mL and 1.25 mg/3 mL. (3)
Source: FDA prescribing information (DailyMed). Set ID: 29eae75d-93da-7a5a-e063-6394a90ac0c0. SPL document ID: 29ead193-b33d-7f78-e063-6294a90a7ef4. Label effective date: December 24, 2024. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Levalbuterol (FDA label)
The following serious adverse reactions are described below and elsewhere in the labeling: Paradoxical bronchospasm [see Warnings and Precautions (5.1) ] Cardiovascular effects [see Warnings and Precautions (5.4) ] Immediate hypersensitivity reactions [see Warnings and Precautions (5.6) ] Hypokalemia [see Warnings and Precautions (5.8) ] Most common adverse reactions are: palpitations, chest pain, tachycardia, headache, dizziness, tremor and nervousness. (6) To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA LLC at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of the drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Source: FDA prescribing information (DailyMed). Set ID: 29eae75d-93da-7a5a-e063-6394a90ac0c0. SPL document ID: 29ead193-b33d-7f78-e063-6294a90a7ef4. Label effective date: December 24, 2024. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Levalbuterol (FDA label)
Levalbuterol inhalation solution is contraindicated in patients with a history of hypersensitivity to levalbuterol or racemic albuterol. Reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema [see Warnings and Precautions (5.6) ]. Hypersensitivity to levalbuterol or racemic albuterol. (4)
Source: FDA prescribing information (DailyMed). Set ID: 29eae75d-93da-7a5a-e063-6394a90ac0c0. SPL document ID: 29ead193-b33d-7f78-e063-6294a90a7ef4. Label effective date: December 24, 2024. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Levalbuterol (FDA label)
Life-threatening paradoxical bronchospasm may occur. Discontinue levalbuterol inhalation solution immediately and treat with alternative therapy. (5.1) Need for more doses of levalbuterol inhalation solution than usual may be a sign of deterioration of asthma and requires reevaluation of treatment. (5.2) Levalbuterol inhalation solution is not a substitute for corticosteroids. (5.3) Cardiovascular effects may occur. Consider discontinuation of levalbuterol inhalation solution if these effects occur. Use with caution in patients with underlying cardiovascular disorders. (5.4) Excessive use may be fatal. Do not exceed recommended dose. (5.5) Immediate hypersensitivity reactions may occur. Discontinue levalbuterol inhalation solution immediately. (5.6) Hypokalemia and changes in blood glucose may occur. ( 5.7 , 5.8 ) 5.1 Paradoxical Bronchospasm Levalbuterol inhalation solution can produce paradoxical bronchospasm, which may be life-threatening. If paradoxical bronchospasm occurs, levalbuterol inhalation solution should be discontinued immediately and alternative therapy instituted.
Source: FDA prescribing information (DailyMed). Set ID: 29eae75d-93da-7a5a-e063-6394a90ac0c0. SPL document ID: 29ead193-b33d-7f78-e063-6294a90a7ef4. Label effective date: December 24, 2024. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Levalbuterol (FDA label)
Other short-acting sympathomimetic aerosol bronchodilators and adrenergic drugs: May potentiate effect. (7.1) Beta-blockers: May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. Patients with asthma should not normally be treated with beta-blockers. (7.2) Diuretic: May worsen electrocardiographic changes or hypokalemia associated with diuretic may worsen. Consider monitoring potassium levels. (7.3) Digoxin: May decrease serum digoxin levels. Consider monitoring digoxin levels. (7.4) Monoamine oxidase inhibitors (MAOs) or tricyclic antidepressants: May potentiate effect of albuterol on the cardiovascular system. (7.5) 7.1 Short-Acting Bronchodilators Avoid concomitant use of other short-acting sympathomimetic bronchodilators or epinephrine in patients being treated with levalbuterol inhalation solution. If additional adrenergic drugs are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects. 7.2 Beta-blockers Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-adrenergic agonists such as levalbuterol inhalation solution, but may produce severe bronchospasm in asthmatic patients.
Source: FDA prescribing information (DailyMed). Set ID: 29eae75d-93da-7a5a-e063-6394a90ac0c0. SPL document ID: 29ead193-b33d-7f78-e063-6294a90a7ef4. Label effective date: December 24, 2024. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.